On February 7, Richard Bernstein, the CEO of Richard Bernstein Advisors, joined ‘The Exchange’ on CNBC to discuss the current state of the equity markets and his firm’s macro-driven investment strategy. Bernstein emphasized that a broadening of the market, which had been occurring in fits and starts since the end of October, was an extraordinarily healthy development. He expressed surprise that the market remained narrow for so long, given the strength of the economy, and noted that nominal GDP last quarter exceeded 8%. He argued that the market is finally beginning to broaden as investors accept that corporate profits are stronger and more widespread than previously anticipated
On February 4, Stephen Parker, JPMorgan Private Bank co-head of global investment strategy, appeared on CNBC’s ‘Squawk Box’ to discuss the latest market trends and the 2026 outlook. Parker argued that the current market action is very healthy, and specifically noted that the tech sector is currently the worst-performing sector in the S&P 500. This shift represents a broadening story where investors are rotating away from the tech concentration and anxiety of the last few years toward a broader recovery.
That being said, we’re here with a list of the 11 best value stocks to buy now.

Our Methodology
We used screeners to identify stocks that are trading below a forward P/E of 15, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on February 21.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
11 Best Value Stocks to Buy Now
11. Vale (NYSE:VALE)
Vale (NYSE:VALE) is one of the best value stocks to buy now. On February 12, Vale reported its full year 2025 financial and operational performance, exceeding production guidance across all key minerals. Iron ore production rose to 336 million tons, while copper and nickel production saw double-digit jumps of 10% and 11%, respectively. This operational surge translated into a 17% year-over-year increase in pro forma EBITDA for Q4, reaching $4.8 billion. Notably, the base metals division more than doubled its EBITDA contribution, signaling a strategic pivot toward energy-transition materials.
The company achieved major milestones in safety and sustainability, fulfilling its commitment to eliminate all high-risk emergency level 3 dams by the end of 2025. Financial discipline remained a core theme, as Vale reduced its net debt to $15.6 billion and achieved significant cost reductions; nickel all-in costs fell by 35%, and iron ore all-in costs were reduced to $54 per ton.
To unlock further value, Vale (NYSE:VALE) launched the Novo Carajás program to double copper output and continues to focus on operational reliability in its nickel business, aiming for cash flow neutrality by the end of 2026.
Vale (NYSE:VALE), together with its subsidiaries, produces iron ore and nickel in Asia, the Americas, Europe, and internationally. It operates through two segments: Iron Solutions and Energy Transition Materials.
10. Equinor (NYSE:EQNR)
Equinor (NYSE:EQNR) is one of the best value stocks to buy now. On February 5, Equinor and Eneco entered into a five-year gas supply agreement, securing up to 0.5 billion cubic meters/bcm of natural gas per year for the Dutch market. Deliveries to the Netherlands’ gas grid commenced earlier on February 1. This partnership reinforces the long-standing relationship between the Norwegian energy giant and the Rotterdam-based utility provider, which serves over two million customers across the Netherlands, Belgium, Germany, and the UK.
The deal focuses on the sustainability quality of the gas, which boasts a greenhouse gas footprint lower than the European average. Because production and transport on the Norwegian continental shelf are highly optimized, Eneco expects to reduce its reported CO2 emissions by more than 10% through this contract. The agreement uses the Attributes SAS digital platform to provide independent, transparent tracking of emissions data, ensuring that the guarantees of origin are verified by Norwegian authorities.
The agreement is a balance between energy security and climate goals. The Eneco CEO noted that while natural gas remains a necessary bridge in the energy mix, sourcing the lowest-emission options available is critical to their One Planet goal of climate neutrality. Equinor’s (NYSE:EQNR) Senior Vice President added that this contract serves as a model for how European energy players can use Norwegian gas to meet both reliability and sustainability standards.
Equinor (NYSE:EQNR) is an energy company that explores, produces, transports, refines, and markets petroleum and other forms of energy in Norway and internationally.
9. Enterprise Products Partners (NYSE:EPD)
Enterprise Products Partners (NYSE:EPD) is one of the best value stocks to buy now. On February 3, Enterprise Products Partners reported its Q4 2025 earnings report, with an EBITDA of $2.7 billion. The company’s quarterly revenue of $13.79 billion was a slight 2.87% decline year-over-year, but still surpassed Street estimates by $1.43 billion. EPS of $0.75 also beat guidance by $0.06.
This growth was fueled by the integration of new assets, such as the Mentone West and Orion projects, alongside an expansion in the company’s NGL export franchise. Strategically, Enterprise Products Partners (NYSE:EPD) is heavily investing in its future, with $4.4 billion dedicated to organic growth capital in 2025. Key projects like the Neches River facility expansion are currently ramping up, with full ethane utilization expected by Q2 2026.
The company also highlighted its successful collaboration with ExxonMobil on the Bahia NGL pipeline. While the firm maintains a strong liquidity position of $5.2 billion and a 3.3x leverage ratio, it noted that 2025 margins were pressured by lower oil prices and narrower spreads in commodity-sensitive sectors like propylene. Looking ahead, management anticipates modest growth in 2026, likely at the lower end of the 3-5% range, followed by a double-digit growth surge in 2027 as major projects reach full capacity.
Enterprise Products Partners (NYSE:EPD) provides midstream energy services to producers and consumers of natural gas, NGLs, crude oil, petrochemicals, and refined products. It operates in four segments: NGL Pipelines & Services, Crude Oil Pipelines & Services, Natural Gas Pipelines & Services, and Petrochemical & Refined Products Services.
8. Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best value stocks to buy now. On February 19, Regeneron Pharmaceuticals announced that the FDA accepted its BLA for garetosmab for Priority Review. This investigational monoclonal antibody is designed to treat adults with fibrodysplasia ossificans progressiva/FOP, which is an ultra-rare and devastating genetic disorder where muscles and connective tissues are progressively replaced by bone.
If approved, garetosmab would be the first treatment proven to significantly reduce both the number and volume of these abnormal bone lesions, with an FDA decision expected by August this year. The application is supported by the Phase 3 OPTIMA trial, which showed dramatic results in adult patients. Over 56 weeks, patients receiving garetosmab experienced a 90% to 94% reduction in the total number of new bone lesions compared to those on a placebo. Furthermore, a post-hoc analysis revealed a more than 99% reduction in the mean total volume of new abnormal bone formation.
The treatment works by neutralizing Activin A, which is a protein that Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) scientists identified as a critical driver of the locking bone growth characteristic of FOP. FOP is a relentless condition that often leads to a complete loss of mobility; most patients require a wheelchair by age 30, and the median survival age is ~56 years. Regeneron plans to initiate the OPTIMA 2 trial later this year to evaluate the safety and efficacy of garetosmab in children and adolescents.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
7. Brookfield Corporation (NYSE:BN)
Brookfield Corporation (NYSE:BN) is one of the best value stocks to buy now. On February 12, Brookfield Corporation reported financial results for the full year 2025, headlined by distributable earnings of $6 billion and a 22% surge in fee-related earnings. The company’s total fee-bearing capital crossed the $600 billion mark, driven by its ability to raise $112 billion in new capital during the year.
The company’s Wealth Solutions (insurance) segment emerged as a primary growth engine, with earnings rising 24% to $1.7 billion and assets under management exceeding $140 billion. To further scale this division, Brookfield announced plans to merge its insurance entity, BNT, directly into Brookfield Corporation within the next 12 months. This simplification is designed to give the insurance business full access to Brookfield’s $180 billion capital base, enabling it to compete more effectively in global annuity and Property & Casualty markets.
Despite the overall growth, the company acknowledged ongoing challenges in the global real estate sector, where market sentiment continues to lag behind physical property fundamentals. However, Brookfield Corporation (NYSE:BN) reported high leasing activity, covering 17 million square feet, with rents on new office leases averaging 18% higher than those expiring.
Brookfield Corporation (NYSE:BN) is a multi-asset manager focused on real estate, credit, renewable power & transition, infrastructure, venture capital, and private equity, including growth capital & emerging growth investments.
6. GSK (NYSE:GSK)
GSK (NYSE:GSK) is one of the best value stocks to buy now. On February 17, GSK released new real-world evidence showing that its RSV (respiratory syncytial virus) vaccine, Arexvy, is associated with significant reductions in hospitalizations and severe complications among adults aged 60 and older. The data, drawn from a large-scale US study of over 2.5 million people, showed a 75.6% VE (vaccine effectiveness) against RSV-related hospitalization.
Notably, the study also found that the vaccine was associated with a 63.1% reduction in major adverse cardiovascular events, such as heart attacks and strokes, during RSV-related hospital stays. The research also highlighted the vaccine’s impact on underlying respiratory conditions. Among patients with COPD (chronic obstructive pulmonary disease), Arexvy was associated with a 74.4% reduction in severe flare-ups; for those with asthma, the reduction was 61.6%.
A separate nationwide study in Denmark even observed a 100% VE in preventing RSV-related hospitalizations among a specific cohort of COPD patients aged 60 and older. While these observational findings do not prove direct causation, they suggest that vaccination may play a critical role in preventing the cascading health failures often triggered by an RSV infection.
GSK (NYSE:GSK), together with its subsidiaries, researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat disease in the UK, the US, and internationally.
5. Rio Tinto Group (NYSE:RIO)
Rio Tinto Group (NYSE:RIO) is one of the best value stocks to buy now. On February 19, Rio Tinto reported earnings for the full year 2025, which was highlighted by a 9% increase in underlying EBITDA and an 8% rise in copper equivalent production. Despite a stable underlying earnings figure of $10.9 billion, the company hit annual production records for both copper and bauxite. This was supported by a $650 million run rate in productivity benefits, which helped lower copper unit costs by 5%.
The company’s focus shifted heavily toward future-facing metals. Copper EBITDA more than doubled to $7.4 billion, while Aluminum EBITDA grew by 20%. To secure long-term growth, Rio Tinto maintained capital expenditure at the high end of its guidance ($11 billion) and completed the Arcadium acquisition, which contributed to an increase in net debt to $14.4 billion.
While the financial outlook remains strong, Rio Tinto Group (NYSE:RIO) faces several headwinds entering 2026. Production volume growth is expected to be more muted due to planned site closures and declining ore grades. In the Pilbara iron ore region, unit costs are projected to rise slightly to between $23 and $25 per ton.
Rio Tinto Group (NYSE:RIO) explores, mines, and processes mineral resources worldwide. The company operates through Iron Ore, Aluminium & Lithium, and Copper segments.
4. Bristol-Myers Squibb Company (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best value stocks to buy now. On February 17, Bristol Myers Squibb announced that the FDA accepted its NDA for iberdomide, which is an investigational treatment for patients with relapsed or refractory multiple myeloma/RRMM. If approved, iberdomide would become the first in a new class of oral medicines known as cereblon E3 ligase modulator agents. The FDA granted the application Priority Review and Breakthrough Therapy Designation, setting a target action date of August 17 this year.
The application is supported by data from the Phase 3 EXCALIBER-RRMM trial, which compared iberdomide in combination with daratumumab and dexamethasone against a standard three-drug regimen. A key highlight of this filing is the use of Minimal Residual Disease/MRD negativity as a primary endpoint. MRD measures the tiny number of cancer cells remaining in the body that traditional tests cannot find; achieving MRD negativity is a highly sensitive indicator that a treatment is effectively clearing the disease and may predict longer periods of remission.
Iberdomide works through targeted protein degradation, a process where the drug tags specific cancer-promoting proteins for destruction by the cell’s internal recycling system. This approach builds on Bristol-Myers Squibb Company’s (NYSE:BMY) long-standing history with immunomodulatory drugs, aiming to provide a more potent oral option with a manageable safety profile.
Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
3. British American Tobacco (NYSE:BTI)
British American Tobacco (NYSE:BTI) is one of the best value stocks to buy now. On February 12, British American Tobacco reported its full-year 2025 earnings report, which was marked by a 2.1% increase in group revenue and 3.4% rise in adjusted profit, driven by a resilient performance in traditional combustibles and an acceleration in New Categories. The company added 4.7 million smokeless consumers, bringing its total to 34.1 million, and remains on track to deliver more than £50 billion in free cash flow by 2030.
In the New Categories segment, modern oral products, led by the Velo brand, grew by 48% globally, with the Velo Plus launch in the US achieving a #2 market position within its first year. Conversely, vapor revenue declined by ~9% due to the prevalence of illicit products in the US and Canada, though H2 of the year showed recovery as enforcement efforts increased. Heated products faced stiff competition in Asia, but the company is hopeful that the premium glo Hilo and next-gen glo HYPER devices will regain market share.
Looking ahead to 2026, British American Tobacco (NYSE:BTI) expects to return to its mid-term growth algorithm of 3-5% revenue growth and 4-6% profit growth. To fund its transformation into a predominantly smokeless business by 2035, the company is intensifying its productivity programs, targeting an additional £2 billion in savings by 2030.
British American Tobacco (NYSE:BTI) provides tobacco and nicotine products to consumers in the US, Europe, Latin America, Canada, the Asia-Pacific, the Middle East, Central Asia, Caucasus, and Africa.
2. Merck & Co. Inc. (NYSE:MRK)
Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks to buy now. On February 19, Merck announced positive second-season findings from the Phase 3 SMART trial evaluating ENFLONSIA (clesrovimab) in infants and children under 2 years of age at increased risk for severe respiratory syncytial virus/RSV. The data focused on vulnerable children, most with chronic lung or congenital heart disease, who received the monoclonal antibody at the start of their second RSV season.
These results showed that the serum concentrations of the antibody in high-risk children were similar to those seen in healthy infants from previous pivotal trials, supporting the potential for extended protection. The safety profile of ENFLONSIA during the second season remained consistent with observations from the first season and previous studies.
Common side effects included irritability, somnolence, and injection-site reactions, with no drug-related serious adverse events reported. ENFLONSIA, which was FDA-approved in June 2025 for infants entering their first RSV season, is a long-acting monoclonal antibody designed to provide five months of protection with a single dose regardless of weight. Merck & Co. Inc. (NYSE:MRK) intends to share these new results with the FDA and other global regulatory authorities to seek an expanded indication for high-risk children entering their second RSV season.
Merck & Co. Inc. (NYSE:MRK) is a healthcare company that offers human health pharmaceuticals for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
1. AbbVie Inc. (NYSE:ABBV)
AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20, the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults with chronic lymphocytic leukemia/CLL. This establishes the first and only all-oral, fixed-duration regimen for previously untreated patients, providing a new alternative to traditional chemoimmunotherapy.
By combining two classes of oral medications, the treatment offers patients the potential for periods of time off therapy, marking a significant advancement in the long-term management of this common adult leukemia. The approval is based on results from the Phase 3 AMPLIFY trial, which demonstrated that the VENCLEXTA and acalabrutinib combination significantly reduced the risk of disease progression or death by 35% compared to standard chemoimmunotherapy.
The safety profile remained consistent with the known effects of each drug, with the most common adverse reactions including neutropenia, headache, and diarrhea. VENCLEXTA, developed by AbbVie Inc. (NYSE:ABBV) and Roche, works by inhibiting the BCL-2 protein to help restore the natural self-destruction process of cancer cells. While this new combination expands flexibility for providers and patients, it does carry risks of serious side effects such as tumor lysis syndrome, which requires preventative hydration and close monitoring by healthcare professionals.
AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches & develops, manufactures, commercializes, and sells medicines and therapies worldwide.
While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.





